AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. OBIO
  4. [Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) reported insider trading activity through a Form 4 filing for director Pamela Ann Connealy. On June 24, 2025, Connealy received two equity awards:

  • 12,422 Restricted Stock Units (RSUs) with zero exercise price, bringing her total direct ownership to 33,711 shares
  • 36,797 Stock Options with an exercise price of $3.22, expiring June 24, 2035

Both awards vest in a single installment at the earlier of: (1) one-year anniversary of the grant date, or (2) the 2026 Annual Meeting of Stockholders, subject to continuous service. The transaction was executed pursuant to the company's director compensation program, with the filing submitted by Andrew Taylor as attorney-in-fact on June 26, 2025.

Orchestra BioMed Holdings (OBIO) ha comunicato un'attivit脿 di insider trading tramite una dichiarazione Form 4 relativa alla direttrice Pamela Ann Connealy. Il 24 giugno 2025, Connealy ha ricevuto due premi azionari:

  • 12.422 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a zero, portando la sua propriet脿 diretta totale a 33.711 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$, con scadenza il 24 giugno 2035

Entrambi i premi maturano in un'unica tranche al verificarsi della prima delle seguenti condizioni: (1) il primo anniversario della data di concessione, oppure (2) l'Assemblea Annuale degli Azionisti del 2026, subordinati alla continuit脿 del servizio. La transazione 猫 stata effettuata in conformit脿 al programma di compensazione per i direttori della societ脿, con la dichiarazione presentata da Andrew Taylor in qualit脿 di procuratore il 26 giugno 2025.

Orchestra BioMed Holdings (OBIO) report贸 una actividad de operaciones internas mediante una presentaci贸n del Formulario 4 para la directora Pamela Ann Connealy. El 24 de junio de 2025, Connealy recibi贸 dos premios en acciones:

  • 12,422 Unidades Restringidas de Acciones (RSUs) sin precio de ejercicio, aumentando su propiedad directa total a 33,711 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22, que expiran el 24 de junio de 2035

Ambos premios se consolidan en un solo pago al cumplirse la primera de las siguientes condiciones: (1) el primer aniversario de la fecha de concesi贸n, o (2) la Reuni贸n Anual de Accionistas de 2026, sujeto a servicio continuo. La transacci贸n se realiz贸 conforme al programa de compensaci贸n para directores de la empresa, con la presentaci贸n realizada por Andrew Taylor como apoderado el 26 de junio de 2025.

Orchestra BioMed Holdings (OBIO)電� 鞚挫偓 Pamela Ann Connealy鞐� 甏�頃� 雮措秬鞛� 瓯半灅 頇滊彊鞚� Form 4 鞁犼碃靹滊ゼ 韱淀暣 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 24鞚�, Connealy電� 霊� 臧�歆� 欤检嫕 氤挫儊鞚� 氚涭晿鞀惦媹雼�:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓臧�瓴╈澊 鞐嗢溂氅�, 攴鸽厐鞚� 歆侅爲 靻岇湢 欤检嫕 齑濎垬電� 33,711欤缄皜 霅橃棃鞀惦媹雼�
  • 36,797 欤检嫕 毵れ垬靹犿儩甓�鞙茧 頄夓偓臧�瓴╈潃 $3.22鞚措┌, 毵岆鞚检潃 2035雲� 6鞗� 24鞚检瀰雼堧嫟

霊� 氤挫儊 氇憪 雼れ潓 欷� 牍犽ジ 鞁滌爯鞐� 雼澕 攵勴暊搿� 頇曥爼霅橂┌: (1) 攵�鞐澕搿滊秬韯� 1欤茧厔, 霕愲姅 (2) 2026雲� 欤检＜齑濏殞鞚措┌, 歆�靻嶌爜鞚� 攴茧臧� 臁瓣贝鞛呺媹雼�. 鞚� 瓯半灅電� 須岇偓鞚� 鞚挫偓 氤挫儊 頂勲攴鸽灗鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 2025雲� 6鞗� 26鞚� Andrew Taylor臧� 雽�毽澑 鞛愱博鞙茧 鞁犼碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.

Orchestra BioMed Holdings (OBIO) a d茅clar茅 une activit茅 d鈥檌niti茅 via un d茅p么t de formulaire 4 concernant la directrice Pamela Ann Connealy. Le 24 juin 2025, Connealy a re莽u deux attributions d鈥檃ctions :

  • 12 422 unit茅s d鈥檃ctions restreintes (RSU) sans prix d鈥檈xercice, portant sa d茅tention directe totale 脿 33 711 actions
  • 36 797 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 3,22 $, expirant le 24 juin 2035

Les deux attributions seront acquises en une seule fois 脿 la premi猫re des dates suivantes : (1) le premier anniversaire de la date d鈥檃ttribution, ou (2) l鈥檃ssembl茅e g茅n茅rale annuelle des actionnaires de 2026, sous r茅serve d鈥檜n service continu. La transaction a 茅t茅 r茅alis茅e conform茅ment au programme de r茅mun茅ration des administrateurs de la soci茅t茅, le d茅p么t ayant 茅t茅 soumis par Andrew Taylor en tant que mandataire le 26 juin 2025.

Orchestra BioMed Holdings (OBIO) meldete Insiderhandel-Aktivit盲ten durch eine Form 4-Einreichung f眉r die Direktorin Pamela Ann Connealy. Am 24. Juni 2025 erhielt Connealy zwei Aktienzuteilungen:

  • 12.422 Restricted Stock Units (RSUs) ohne Aus眉bungspreis, wodurch ihr direkter Gesamtbesitz auf 33.711 Aktien anstieg
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $, die am 24. Juni 2035 verfallen

Beide Zuteilungen werden in einer einzigen Tranche f盲llig, und zwar zu dem fr眉heren Zeitpunkt von: (1) dem einj盲hrigen Jubil盲um des Gew盲hrungsdatums oder (2) der Hauptversammlung 2026, vorbehaltlich ununterbrochener Dienstzeit. Die Transaktion wurde im Rahmen des Verg眉tungsprogramms f眉r Direktoren des Unternehmens durchgef眉hrt, wobei die Einreichung am 26. Juni 2025 von Andrew Taylor als Bevollm盲chtigter vorgenommen wurde.

Positive
  • None.
Negative
  • None.

Orchestra BioMed Holdings (OBIO) ha comunicato un'attivit脿 di insider trading tramite una dichiarazione Form 4 relativa alla direttrice Pamela Ann Connealy. Il 24 giugno 2025, Connealy ha ricevuto due premi azionari:

  • 12.422 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a zero, portando la sua propriet脿 diretta totale a 33.711 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$, con scadenza il 24 giugno 2035

Entrambi i premi maturano in un'unica tranche al verificarsi della prima delle seguenti condizioni: (1) il primo anniversario della data di concessione, oppure (2) l'Assemblea Annuale degli Azionisti del 2026, subordinati alla continuit脿 del servizio. La transazione 猫 stata effettuata in conformit脿 al programma di compensazione per i direttori della societ脿, con la dichiarazione presentata da Andrew Taylor in qualit脿 di procuratore il 26 giugno 2025.

Orchestra BioMed Holdings (OBIO) report贸 una actividad de operaciones internas mediante una presentaci贸n del Formulario 4 para la directora Pamela Ann Connealy. El 24 de junio de 2025, Connealy recibi贸 dos premios en acciones:

  • 12,422 Unidades Restringidas de Acciones (RSUs) sin precio de ejercicio, aumentando su propiedad directa total a 33,711 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22, que expiran el 24 de junio de 2035

Ambos premios se consolidan en un solo pago al cumplirse la primera de las siguientes condiciones: (1) el primer aniversario de la fecha de concesi贸n, o (2) la Reuni贸n Anual de Accionistas de 2026, sujeto a servicio continuo. La transacci贸n se realiz贸 conforme al programa de compensaci贸n para directores de la empresa, con la presentaci贸n realizada por Andrew Taylor como apoderado el 26 de junio de 2025.

Orchestra BioMed Holdings (OBIO)電� 鞚挫偓 Pamela Ann Connealy鞐� 甏�頃� 雮措秬鞛� 瓯半灅 頇滊彊鞚� Form 4 鞁犼碃靹滊ゼ 韱淀暣 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 24鞚�, Connealy電� 霊� 臧�歆� 欤检嫕 氤挫儊鞚� 氚涭晿鞀惦媹雼�:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓臧�瓴╈澊 鞐嗢溂氅�, 攴鸽厐鞚� 歆侅爲 靻岇湢 欤检嫕 齑濎垬電� 33,711欤缄皜 霅橃棃鞀惦媹雼�
  • 36,797 欤检嫕 毵れ垬靹犿儩甓�鞙茧 頄夓偓臧�瓴╈潃 $3.22鞚措┌, 毵岆鞚检潃 2035雲� 6鞗� 24鞚检瀰雼堧嫟

霊� 氤挫儊 氇憪 雼れ潓 欷� 牍犽ジ 鞁滌爯鞐� 雼澕 攵勴暊搿� 頇曥爼霅橂┌: (1) 攵�鞐澕搿滊秬韯� 1欤茧厔, 霕愲姅 (2) 2026雲� 欤检＜齑濏殞鞚措┌, 歆�靻嶌爜鞚� 攴茧臧� 臁瓣贝鞛呺媹雼�. 鞚� 瓯半灅電� 須岇偓鞚� 鞚挫偓 氤挫儊 頂勲攴鸽灗鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 2025雲� 6鞗� 26鞚� Andrew Taylor臧� 雽�毽澑 鞛愱博鞙茧 鞁犼碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.

Orchestra BioMed Holdings (OBIO) a d茅clar茅 une activit茅 d鈥檌niti茅 via un d茅p么t de formulaire 4 concernant la directrice Pamela Ann Connealy. Le 24 juin 2025, Connealy a re莽u deux attributions d鈥檃ctions :

  • 12 422 unit茅s d鈥檃ctions restreintes (RSU) sans prix d鈥檈xercice, portant sa d茅tention directe totale 脿 33 711 actions
  • 36 797 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 3,22 $, expirant le 24 juin 2035

Les deux attributions seront acquises en une seule fois 脿 la premi猫re des dates suivantes : (1) le premier anniversaire de la date d鈥檃ttribution, ou (2) l鈥檃ssembl茅e g茅n茅rale annuelle des actionnaires de 2026, sous r茅serve d鈥檜n service continu. La transaction a 茅t茅 r茅alis茅e conform茅ment au programme de r茅mun茅ration des administrateurs de la soci茅t茅, le d茅p么t ayant 茅t茅 soumis par Andrew Taylor en tant que mandataire le 26 juin 2025.

Orchestra BioMed Holdings (OBIO) meldete Insiderhandel-Aktivit盲ten durch eine Form 4-Einreichung f眉r die Direktorin Pamela Ann Connealy. Am 24. Juni 2025 erhielt Connealy zwei Aktienzuteilungen:

  • 12.422 Restricted Stock Units (RSUs) ohne Aus眉bungspreis, wodurch ihr direkter Gesamtbesitz auf 33.711 Aktien anstieg
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $, die am 24. Juni 2035 verfallen

Beide Zuteilungen werden in einer einzigen Tranche f盲llig, und zwar zu dem fr眉heren Zeitpunkt von: (1) dem einj盲hrigen Jubil盲um des Gew盲hrungsdatums oder (2) der Hauptversammlung 2026, vorbehaltlich ununterbrochener Dienstzeit. Die Transaktion wurde im Rahmen des Verg眉tungsprogramms f眉r Direktoren des Unternehmens durchgef眉hrt, wobei die Einreichung am 26. Juni 2025 von Andrew Taylor als Bevollm盲chtigter vorgenommen wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Connealy Pamela Ann
(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE
(Street)
NEW YORK PA 18938
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 06/24/2025 A 12,422(1) A $0 33,711 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.22 06/24/2025 A 36,797 (2) 06/24/2035 Common Stock 36,797 $0 36,797 D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
2. The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
/s/ Andrew Taylor, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at OBIO on June 24, 2025?

Director Pamela Ann Connealy received two equity awards: 12,422 restricted stock units (RSUs) and 36,797 stock options with an exercise price of $3.22. Both awards were granted on June 24, 2025.

What is the vesting schedule for OBIO director Pamela Connealy's June 2025 stock awards?

Both the RSUs and stock options will vest in one installment on the earlier of: (1) the one-year anniversary of the grant date (June 24, 2026) or (2) the date of OBIO's 2026 Annual Meeting of Stockholders, subject to continuous service.

How many shares of OBIO does Pamela Connealy own after the June 2025 transaction?

Following the transaction, Pamela Connealy directly owns 33,711 shares of OBIO common stock, plus 36,797 unvested stock options and 12,422 unvested RSUs.

What is the exercise price of OBIO stock options granted to director Connealy in June 2025?

The stock options were granted with an exercise price of $3.22 per share and have an expiration date of June 24, 2035.

When do Pamela Connealy's OBIO stock options expire?

The stock options granted to Pamela Connealy on June 24, 2025, expire on June 24, 2035, giving them a 10-year term from the grant date.
Stock OBIO logo
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

#4473 Ranked by Market Cap
N/A Ranked by Dividends

OBIO Latest News

Aug 26, 2025
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Aug 14, 2025
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
Aug 12, 2025
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Aug 8, 2025
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Aug 5, 2025
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

OBIO Latest SEC Filings

Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 12, 2025
[10-Q] Orchestra BioMed Holdings, Inc. Quarterly Earnings Report

OBIO Stock Data

140.28M
39.91M
16.19%
34.98%
1.31%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE